We are live on ! Find out more
ALBO

Albireo Pharma Inc

Delisted

ALBO was delisted on the 2nd of March, 2023.

35 hedge funds and large institutions have $7.19M invested in Albireo Pharma Inc in 2014 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 8

12% less capital invested

Capital invested by funds: $8.19M → $7.19M (-$999K)

15% less funds holding

Funds holding: 4135 (-6)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

67% less call options, than puts

Call options by funds: $21K | Put options by funds: $64K

Holders
35
Holders Change
-6
Holders Change %
-14.63%
% of All Funds
0.93%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
14
Reduced
8
Closed
9
Calls
$21K
Puts
$64K
Net Calls
-$43K
Net Calls Change
+$22K
Name Holding Trade Value Shares
Change
Change in
Stake
BC
1
Broadfin Capital
New York
$1.77M
Wellington Management Group
2
Wellington Management Group
Massachusetts
$1.38M -$66.5K -1,515 -4%
William Blair & Company
3
William Blair & Company
Illinois
$1.3M +$96.5K +2,198 +22%
Vanguard Group
4
Vanguard Group
Pennsylvania
$693K +$12.9K +294 +2%
FMA
5
FNY Managed Accounts
New York
$422K +$417K +9,500 +890%
Goldman Sachs
6
Goldman Sachs
New York
$297K +$44 +1 +0%
O
7
OrbiMed
New York
$279K
Renaissance Technologies
8
Renaissance Technologies
New York
$240K +$172K +3,915 +186%
Group One Trading
9
Group One Trading
Illinois
$131K +$56.5K +1,287 +64%
SKK
10
Shepherd Kaplan Krochuk
Massachusetts
$107K +$22.4K +510 +23%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$74K
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$73K -$62.6K -1,427 -44%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$73K +$16.1K +367 +25%
BFA
14
BlackRock Fund Advisors
California
$70K +$5.53K +126 +8%
Citadel Advisors
15
Citadel Advisors
Florida
$43K +$28.2K +643 +147%
Deutsche Bank
16
Deutsche Bank
Germany
$37K +$41.1K +936 New
Ameriprise
17
Ameriprise
Minnesota
$36K +$14.4K +328 +57%
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$35K
Northern Trust
19
Northern Trust
Illinois
$34K -$44 -1 -0.1%
FAAS
20
First Allied Advisory Services
California
$27K
CC
21
Cannell & Co
New York
$18K -$29.3K -667 -59%
RCM
22
Rotella Capital Management
Washington
$17K -$24.5K -557 -57%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$16K +$395 +9 +2%
UBS Group
24
UBS Group
Switzerland
$6K +$5.79K +132 New
BIM
25
BlackRock Investment Management
Delaware
$5K

ALBO Hedge Fund Activity: Q4 2014 in Review

35 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q4 2014, worth a combined $7.19M — down 12% from $8.19M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ALBO and 4 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 14 added.

The largest buyer was FNY Managed Accounts, adding an estimated $417K. The largest seller was First New York Securities, exiting entirely with an estimated $453K sold.

  • 35 institutional investors held Albireo Pharma Inc (ALBO) as of Q4 2014, down from 41 in Q3 2014.
  • Funds reported $7.19M of Albireo Pharma Inc stock for Q4 2014, down 12% quarter-over-quarter.
  • 4 funds opened new Albireo Pharma Inc positions in Q4 2014 and 9 closed out, a net change of -5 holders.
  • The largest Albireo Pharma Inc buyer in Q4 2014 was FNY Managed Accounts, an estimated $417K added.
  • The largest Albireo Pharma Inc seller in Q4 2014 was First New York Securities, an estimated $453K sold.

Based on aggregated 13F filings for Q4 2014.